Business Context and Reporting Period
Company: The Clorox Company (CLX)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended December 31, 2024 (Fiscal Q2 2025)
Business Overview: A leading multinational manufacturer of consumer and professional products operating in Health and Wellness, Household, Lifestyle, and International segments. The company recently completed the divestiture of its Better Health Vitamins, Minerals, and Supplements (VMS) business and continues to recover from the August 2023 cyberattack.
Key Financial Metrics
| Metric ($ millions) | 3 Months Ended 12/31/24 | 6 Months Ended 12/31/24 | 3 Months Ended 12/31/23 | 6 Months Ended 12/31/23 |
|---|---|---|---|---|
| Net Sales | $1,686 | $3,448 | $1,990 | $3,376 |
| Gross Profit | $738 | $1,545 | $866 | $1,398 |
| Gross Margin | 43.8% | 44.8% | 43.5% | 41.4% |
| Net Earnings (Attributable to Clorox) | $193 | $292 | $93 | $115 |
| Diluted EPS | $1.54 | $2.34 | $0.75 | $0.92 |
| Operating Cash Flow | N/A | $401 | N/A | $173 |
| Cash and Equivalents (Ending) | $290 | $290 | N/A | N/A |
| Total Debt (Current + Long-term) | $2,672 | $2,672 | N/A | N/A |
Note: Total Debt calculated as Notes and loans payable ($189) + Long-term debt ($2,483).
Material Changes vs. Prior Period
- Revenue: Net sales decreased 15% year-over-year for the quarter ($1,686M vs. $1,990M) primarily due to the divestiture of the Better Health VMS business and lapping the retail inventory restoration from the prior year's cyberattack. For the six-month period, sales increased 2% ($3,448M vs. $3,376M) as cyberattack recovery impacts were lapped, partially offset by divestitures.
- Profitability: Diluted EPS increased 105% for the quarter and 154% for the six months. This significant improvement is largely driven by the absence of a $171M pension settlement charge and $49M in cyberattack costs recorded in the prior year, alongside cost savings and insurance recoveries in the current period.
- Divestitures: The company recorded a $118M after-tax loss on the divestiture of the Better Health VMS business in the six months ended December 31, 2024. The Argentina business was divested in the prior fiscal year.
- Cash Flow: Operating cash flow for the six months ended December 31, 2024, was $401M, a substantial increase from $173M in the prior year, driven by higher cash earnings and lower tax payments.
Guidance, Outlook, and Risks
- Outlook: Management anticipates a volatile and challenging operating environment for the remainder of fiscal year 2025 due to elevated interest rates, macroeconomic uncertainty, and geopolitical instability. The company expects to continue generating cost savings from its streamlined operating model.
- Cyberattack Recovery: The company has returned to normalized operations following the August 2023 cyberattack. It recorded $35M in insurance recoveries for the six months ended December 31, 2024, and does not expect significant future costs related to the incident.
- Strategic Investments: The company is investing in digital capabilities and productivity enhancements, incurring $55M in related expenses for the six months ended December 31, 2024. Implementation of a new ERP system began in Q1 2025.
- Subsequent Event: The venture agreement with Procter & Gamble (P&G) regarding the Glad business will terminate in January 2026. Clorox is required to purchase P&G's 20% interest for cash at fair value (estimated at $531M).
- Risks: Key risks include supply chain disruptions, raw material cost volatility, foreign exchange fluctuations, and the potential for future cybersecurity incidents.
Investor Verification Checklist
- Divestiture Impact: Verify the long-term margin benefits of the Better Health VMS and Argentina divestitures against the one-time $118M loss recorded.
- Cyberattack Costs: Confirm that the $35M in insurance recoveries fully offset remaining incremental costs and that no further material expenses are expected.
- P&G Venture Termination: Assess the liquidity impact of the upcoming $531M cash payment required to buy out P&G's interest in the Glad business in January 2026.
- Organic Growth: Review organic sales growth metrics (reported as -9% for the quarter and +7% for the six months) to understand underlying demand trends excluding divestitures and FX.
- Debt Covenants: Monitor compliance with the Credit Agreement's interest coverage ratio (minimum 4.0x), especially given the current high-interest environment.